A Tale Of Two Pipelines
The Promise And Pitfalls Of IO Exuberance And How To Rethink The Approach To Cancer Innovation
Immuno-oncology has produced some exciting successes, but the field has become intensely crowded. Enormous resources are being poured into duplicative work and shaky hypotheses—overshadowing other pursuits in cancer research while producing limited results. It is time to re-evaluate how the sector should be pursuing innovation in cancer and how it can be smarter in its use of resources—financial investment, talent, bandwidth, patients and data.
You may also be interested in...
Experts from a European data sharing initiative talk to In Vivo about the importance of coordinated computational biology efforts for the future of life sciences innovation and the effective use of artificial intelligence.